CHRNA4 and tularemia: CAP is hypothesized to be able to modify tularemia progression on administration of either ACh as direct stimulator of nAChR or of the reversible acetylcholinesterase (AChE) inhibitor neostigmine, which protects endogenous ACh from splitting by blood AChE.